All Stories

  1. In VitroActivity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants

    Article • Antimicrobial Agents and Chemotherapy, September 2015, ASM Journals

    Dr Thierry Verbinnen

  2. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

    Article • Journal of Hepatology, May 2015, Elsevier

    Dr Thierry Verbinnen

  3. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

    Article • Antiviral Research, April 2015, Elsevier

    Dr Thierry Verbinnen

  4. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial

    Article • The Lancet Infectious Diseases, January 2015, Elsevier

    Dr Thierry Verbinnen

  5. Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy

    Article • Gastroenterology, November 2012, Elsevier

    Dr Thierry Verbinnen

  6. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays

    Article • Journal of Antimicrobial Chemotherapy, June 2012, Oxford University Press (OUP)

    Dr Thierry Verbinnen, Johan Neyts

  7. Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing

    Article • Journal of Virology, August 2010, ASM Journals

    Dr Thierry Verbinnen, Johan Neyts

  8. In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

    Article • Antimicrobial Agents and Chemotherapy, February 2010, ASM Journals

    Dr Thierry Verbinnen

  9. In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

    Article • Antimicrobial Agents and Chemotherapy, January 2009, ASM Journals

    Dr Thierry Verbinnen

  10. Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, April 2007, Elsevier

    Dr Thierry Verbinnen

  11. The 2-5A Pathway and Signal Transduction

    Article • February 2002, Taylor & Francis

    Dr Thierry Verbinnen